查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球骨髓增生异常综合征（MDS）治疗市场 - 2023-2030年
市场调查报告书
商品编码
1290358

全球骨髓增生异常综合征（MDS）治疗市场 - 2023-2030年

Global Myelodysplastic Syndrome (MDS) Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球骨髓增生异常综合症（MDS）治疗市场在2022年达到30.655亿美元，预计到2030年将见证有利可图的增长，达到60.595亿美元。全球骨髓增生异常综合症治疗市场在预测期内（2023-2030年）预计将呈现9.1%的复合增长率。

干细胞移植是推动全球骨髓增生异常综合症治疗市场的主要趋势之一。骨髓增生异常综合征患者的治愈性治疗方案 - 造血干细胞移植（HSCT），也一直是研发工作的主题。通过研究，人们对影响移植成功的因素，如供体选择、调理方案和移植物抗宿主疾病预防技术，有了更好的了解。

此外，骨髓增生异常综合症的免疫疗法的发展是另一个研究和发展领域。这些治疗方法利用身体的免疫系统来寻找和摧毁恶性或病态细胞。例如，免疫检查点抑制剂，如pembrolizumab，在具有特定基因突变的骨髓增生异常综合症患者亚群中显示出良好的前景。 估计在整个预期时间范围内，将推动骨髓增生异常综合症（MDS）治疗市场的增长。

市场动态

研发的进步推动了全球骨髓增生异常综合症治疗市场的增长

研究和开发（R&D）的进步在推动骨髓增生异常综合症治疗领域的进步和创新方面发挥了重要作用。研发工作加深了研究人员对骨髓增生异常综合症的分子机制的理解。这包括确定导致该疾病发展和进展的特定基因突变和异常情况。

通过先进的基因组测序技术，研究人员已经能够确定骨髓增生异常综合症的基因特征，从而能够进行更精确的诊断和有针对性的治疗方法。

根据2022年发表在《血液学和肿瘤学杂志》上的文章，由于MDS的分子和遗传特征，该疾病的发病机制得到了更好的理解，这也加速了全新治疗方法的产生。不同的血液学恶性肿瘤对靶向和免疫治疗反应良好。

低甲基化药物（HMAs）的引入是MDS管理中值得注意的进展之一，特别是高风险MDS。在历史性的随机AZA-001试验中，阿扎胞苷（AZA）大大增加了中位OS，从传统治疗的15个月增加到约24个月。这些统计数字已导致采用AZA作为治疗高风险MDS患者的标准。

与骨髓增生异常综合症治疗相关的副作用正在阻碍全球骨髓增生异常综合症治疗市场在预测期内的增长。

骨髓增生异常综合征的治疗，如化疗或免疫抑制治疗，可能有明显的副作用。这些副作用可能影响病人的生活质量，并对坚持治疗方案构成挑战。

副作用包括咳嗽或呼吸急促，胃痉挛或便秘，出现新的皮疹，皮肤变红，瘙痒，以及持续的头痛，身体任何部位出现新的疼痛或酸痛。

此外，骨髓增生异常综合征的治疗，如化疗药物或造血干细胞移植，可能很昂贵。高昂的治疗费用可能会限制那些没有足够保险或经济来源的患者的治疗。

COVID-19影响分析

COVID-19大流行对骨髓增生异常综合症治疗市场产生了重大影响。根据2022年4月发表在《白血病》上的文章，COVID-19与急性白血病、高危骨髓增生异常综合征、以及造血细胞移植和嵌合抗原受体T治疗后的血液病患者的显著死亡率有关。

虽然严重程度和预后较差，但临床症状和体征与普通人群的报告相似。截至2023年，COVID-19的情况正在恢复，患者可以进入所有的医疗机构，导致全球骨髓增生异常综合症治疗市场的需求增加。

俄罗斯与乌克兰的冲突分析

俄乌战争对骨髓增生异常综合征治疗市场的影响是复杂和多方面的。在地缘政治不稳定和经济不确定的时候，疾病的负担和医疗设施会受到影响。这可能导致治疗方案的可及性不足，造成骨髓增生异常综合征的治疗需求下降。

冲突可能会转移与骨髓增生异常综合症治疗有关的研究和开发活动的资源和注意力。受影响地区的制药公司和研究机构在进行临床试验、收集数据和推进新型疗法方面可能面临挑战。

在直接受冲突影响的地区，医护人员和病人可能会流离失所，导致骨髓增生异常综合症治疗服务中断。患者可能难以进入医疗机构，导致诊断和治疗的延误。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按治疗类型分析
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 患有骨髓增生异常综合症的人口不断增加
    • 限制因素
      • 与药物有关的副作用
    • 机会
      • 骨髓增生异常综合症药物的研究和开发
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第六章：COVID-19分析

  • 对COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：人工智能分析

第九章：按治疗类型

  • 干细胞移植
  • 免疫治疗
  • 化学治疗
    • 低甲基化药物
      • 阿扎胞苷 (Vidaza)
      • 地西他滨(Dacogen)
  • 免疫调节药物
    • 来那度胺（Revlimid）。
    • 其他药物
  • 抗炎药
    • Luspatercept-aamt (REBLOZYL)
    • 其他
  • 其他
    • 阿糖胞苷(Cytosar-U)
    • 多柔比星(Cerubidine)
    • 伊达鲁比星(伊达霉素)
    • inqovi (astx727)

第十章：按终端用户

  • 医院
  • 专业诊所
  • 其他终端用户

第十一章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十二章 ：竞争格局

  • 竞争格局
  • 产品标杆
  • 公司份额分析
  • 主要发展和战略

第十三章 ：公司简介

  • AbbVie Inc.
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Accord Healthcare
  • Bristol-Myers Squibb
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Pharmaceuticals
  • Otsuka America Pharmaceutical Inc.
  • Onconova Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Astex Pharmaceuticals, Inc.

第十四章：附录

简介目录
Product Code: PH2678

Market Overview

The Global Myelodysplastic Syndrome (MDS) Treatment Market reached US$ 3,065.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,059.5 million by 2030. The global myelodysplastic syndrome treatment market is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

Stem cell transplantation is one of the major trends driving the global myelodysplastic syndrome treatment market. A curative therapeutic option for myelodysplastic syndrome patients, hematopoietic stem cell transplantation (HSCT), has also been the subject of R&D work. The factors influencing transplantation success, such as donor selection, conditioning regimens, and graft-versus-host disease preventive techniques, have been better understood via research.

Furthermore, the development of immunotherapies for myelodysplastic syndrome is another area of research and development. These treatments use the immune system of the body to find and destroy malignant or sick cells. For instance, immune checkpoint inhibitors, such as pembrolizumab, have shown promise in subsets of MDS patients with specific genetic mutations. estimated to fuel the growth of the Myelodysplastic Syndrome (MDS) Treatment market throughout the anticipated time frame.

Market Dynamics

Advancements in Research and Development are Boosting the Global Myelodysplastic Syndrome Treatment Market Growth

Advancements in research and development (R&D) have played a significant role in driving progress and innovation in the field of myelodysplastic syndrome treatment. R&D efforts have deepened researchers' understanding of the molecular mechanisms underlying myelodysplastic syndrome. This includes identifying specific genetic mutations and abnormalities that contribute to the development and progression of the disease.

Through advanced genomic sequencing techniques, researchers have been able to characterize the genetic landscape of MDS, allowing for more precise diagnosis and targeted treatment approaches.

As per the article published in the Journal of Hematology and Oncology in 2022, the pathogenesis of the disease has been better understood because of the molecular and genetic characterization of MDS, which has also sped up the creation of brand-new treatments. Different hematologic malignancies have responded well to targeted and immune treatments.

The introduction of hypomethylating drugs (HMAs) is one of the noteworthy advancements in the management of MDS, particularly high-risk-MDS. In the historic randomized AZA-001 trial, azacitidine (AZA) considerably increased the median OS from 15 months with conventional treatments to about 24 months. These statistics have led to the adoption of AZA as the norm for treating individuals with high risk-MDS.

Side Effects Associated with Myelodysplastic Syndrome Treatment are Hampering the Global Myelodysplastic Syndrome Treatment Market Growth in the Forecast Period.

Myelodysplastic syndrome treatments, such as chemotherapy or immunosuppressive therapy, can have significant side effects. These side effects may impact the patient's quality of life and pose challenges in adhering to the treatment regimen.

The side effects include coughing or shortness of breath, stomach cramps or constipation, a new rash, reddening of the skin, itching, and a persistent headache, new pain or soreness anywhere on the body.

In addition, myelodysplastic syndrome treatments, such as chemotherapy drugs or hematopoietic stem cell transplantation, can be expensive. The high cost of treatment may limit access for patients who do not have adequate insurance coverage or financial resources.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the myelodysplastic syndrome treatment market. According to the article published in Leukemia in April 2022, COVID-19 has been linked to a significant mortality rate in hematological patients with acute leukemia, high-risk myelodysplastic syndromes, and following hematopoietic cell transplant and chimeric antigen receptor T treatments.

Although the severity and prognosis were worse, the clinical symptoms and signs were similar to those reported for the general population. As of 2023, the COVID-19 situation is recovering and patients can access all healthcare facilities leading to an increasing demand for the myelodysplastic syndrome treatment market worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the myelodysplastic syndrome treatment market is complex and multifaceted. In times of geopolitical instability and economic uncertainty, the burden of disease and healthcare facilities can be affected. This can result in a lack of accessibility of treatment options resulting in decreased demand for treatment of the myelodysplastic syndrome.

The conflict may divert resources and attention away from research and development activities related to myelodysplastic syndrome treatments. Pharmaceutical companies and research institutions in the affected regions may face challenges in conducting clinical trials, collecting data, and advancing novel therapies.

In regions directly affected by the conflict, healthcare professionals and patients may be displaced, resulting in the disruption of myelodysplastic syndrome treatment services. Patients may have difficulty accessing healthcare facilities, leading to delays in diagnosis and treatment initiation.

Segment Analysis

The global myelodysplastic syndrome treatment market is segmented based on treatment type, end-user, and region.

The Stem Cell Transplant Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The stem cell transplant segment accounted for the highest market stake accounting for approximately 27.3% of the myelodysplastic syndrome treatment market. Patients with myelodysplastic syndromes may benefit from stem cell transplantation as a treatment.

An allogeneic stem cell transplant and an autologous stem cell transplant are the two main varieties of SCT. After the patient's bone marrow is removed during an allogeneic stem cell transplant, the donor's blood-forming stem cells are given to the patient. This kind of transplant is frequently utilized for MDS.

The patient's own stem cells, which were extracted prior to therapy, are given back during an autologous stem cell transplant. Patients with myelodysplastic syndrome are often not candidates for this sort of transplant because their bone marrow includes aberrant stem cells.

The only treatment available today that can induce long-lasting remission is high-dose chemotherapy combined with a bone marrow/stem cell transplant. However, because transplantation carries a higher risk of side effects, it may not be suggested for people who are older or have additional health issues.

An allogeneic transplant, however, might be an option for people between the ages of 50 and 75 after less intense therapy. The surgeon will discuss the risks of transplantation in detail before recommending it. They will also take into account the age and general health, the subtype of myelodysplastic syndrome, the outcomes of any prior treatments, and many other things.

Geographical Analysis

Increasing Research and Development and Advancement in Myelodysplastic Syndrome Treatment Dominate the North American Region

North America is expected to dominate the myelodysplastic syndrome treatment market, accounting for around 41.6% of this market. In December 2022, Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the start of Phase 1 clinical trial of ACLX-002 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes, as well as the continuation of robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma.

Furthermore, in December 2022, Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, presented at the 64th American Society of Haematology (ASH) Annual Meeting and Exposition encouraging Phase 1 dose escalation data from the current Phase 1/1b clinical research of PRGN-3006 UltraCAR-T in patients with r/r AML and higher risk myelodysplastic syndromes.

Competitive Landscape

The major global players in the market include: AbbVie Inc., Accord Healthcare, Bristol-Myers Squibb, Jazz Pharmaceuticals Inc., Novartis AG, Lupin Pharmaceuticals, Otsuka America Pharmaceutical Inc., Onconova Therapeutics, Takeda Pharmaceutical Company Limited, and Astex Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global myelodysplastic syndrome treatment market segmentation based on the treatment type, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of myelodysplastic syndrome treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global myelodysplastic syndrome treatment market report would provide approximately 54 tables, 50 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing population with myelodysplastic syndrome
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the medications
    • 4.1.3. Opportunity
      • 4.1.3.1. Research and development of myelodysplastic syndrome drugs
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.2. Stem Cell Transplant*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Immune Treatments
  • 9.4. Chemotherapy
    • 9.4.1. Hypomethylating Agents
      • 9.4.1.1. Azacitidine (Vidaza)
      • 9.4.1.2. Decitabine (Dacogen)
  • 9.5. Immunomodulatory Drugs
    • 9.5.1. Lenalidomide (Revlimid)
    • 9.5.2. Others
  • 9.6. Anti-anemics
    • 9.6.1. Luspatercept-aamt (REBLOZYL)
    • 9.6.2. Others
  • 9.7. Others
    • 9.7.1. Cytarabine (Cytosar-U)
    • 9.7.2. Daunorubicin (Cerubidine)
    • 9.7.3. Idarubicin (Idamycin)
    • 9.7.4. INQOVI (ASTX727)

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Other End Users

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.5.1. The U.S.
      • 11.2.5.2. Canada
      • 11.2.5.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. The U.K.
      • 11.3.5.3. France
      • 11.3.5.4. Italy
      • 11.3.5.5. Spain
      • 11.3.5.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Brazil
      • 11.4.5.2. Argentina
      • 11.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. Australia
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. AbbVie Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Accord Healthcare
  • 13.3. Bristol-Myers Squibb
  • 13.4. Jazz Pharmaceuticals Inc.
  • 13.5. Novartis AG
  • 13.6. Lupin Pharmaceuticals
  • 13.7. Otsuka America Pharmaceutical Inc.
  • 13.8. Onconova Therapeutics
  • 13.9. Takeda Pharmaceutical Company Limited
  • 13.10. Astex Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us